category,datetime,headline,id,image,related,source,summary,url
company,1768126073,How The Medtronic (MDT) Story Is Evolving After Q2 Results And Analyst Revisions,138069135,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MDT,Yahoo,"The latest update on Medtronic edges its fair value estimate to US$111.05 per share, with a slightly lower discount rate of 8.78% and revenue growth now set at 5.73%, changes that reflect how recent Q2 results and product pipeline momentum are feeding into refreshed models. These tweaks are small but they align with a broader shift in how analysts are framing the story around Medtronic after a run of higher price targets and updated views on execution. Stay tuned to see how you can keep on...",https://finnhub.io/api/news?id=9f56298bc8bbb339bd459fb3f261b01bb3ce8d655bc6b8452e94b53f1698e502
company,1768122731,Is Real‑World MiniMed 780G Data Altering The Investment Case For Medtronic (MDT)?,138069136,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MDT,Yahoo,"A real-world retrospective analysis published in Diabetes Care found that Medtronic’s MiniMed 780G insulin system users met American Diabetes Association time-in-range goals even on days when mealtime boluses were missed, particularly when SmartGuard technology was used with recommended optimal settings. The data, drawn from over 369,000 global CareLink users, highlights how optimized algorithm settings may help ease the daily mealtime decision-making burden that often drives diabetes...",https://finnhub.io/api/news?id=18a632b8e5ff31fa2eb1f5c6c2c0af7e94a90a758f01282662235ead0e1d71cd
